Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Oct;2(5):e147.
doi: 10.1097/HS9.0000000000000147. Epub 2018 Oct 2.

Chronic Myeloproliferative Neoplasms: Some Remaining Challenges

Tariq I Mughal  1 , Giuseppe Saglio  2 , Richard A Van Etten  3
Affiliations
Editorial

Chronic Myeloproliferative Neoplasms: Some Remaining Challenges

Tariq I Mughal et al. Hemasphere. 2018 Oct.
No abstract available

PubMed Disclaimer

References

    1. Mughal TI, Gotlib J, Mesa R, et al. Recent advances in the genomics and therapy of BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res. 2018;67:67–74. - PMC - PubMed
    1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566. - PubMed
    1. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927. - PMC - PubMed
    1. Bower H, Bjorkholm M, Dickman M, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–2857. - PubMed
    1. Huang X, Cortes J, Kantarjian H. Estimation of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118:3123–3127. - PMC - PubMed

Publication types